Emergent Biosolutions Inc (EBS)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NYSE
Market Cap: $298.72M
Last updated: Nov 17, 2026 at 4:15 PM ET
Emergent Biosolutions Inc (EBS) Stock Chart
Emergent Biosolutions (EBS) has a latest price of $5.61 on Nov 17, 2026, 60.1% below its 52-week high of $14.06. Its price fell 44.5% over the past 12 months. The month-end price fell 74.5% over the 10 years through Oct 2026, a compound annual decline of 12.8%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $114.05 in Aug 2020 and its lowest $1.67 in Jan 2024, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart EBS with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for EBS.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price rose 14.7%, and over 6 months it fell 30.4%. The month-end price rose 225.8% over the 3 years through Oct 2026, a compound annual rate of 48.3%.
| Period | Change |
|---|---|
| 1 month | -11.8% |
| 3 months | +14.7% |
| 6 months | -30.4% |
| 12 months | -44.5% |
| 12 months, with dividends | -44.5% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +225.8% | +48.3% |
| 5 years | -85.7% | -32.2% |
| 10 years | -74.5% | -12.8% |
Price by Year
Its best calendar year was 2024, when the price rose 298.3%, and its weakest was 2023, when it fell 79.7%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $6.81 | -44.9% |
| 2025 | $12.36 | +29.3% |
| 2024 | $9.56 | +298.3% |
| 2023 | $2.40 | -79.7% |
| 2022 | $11.81 | -72.8% |
| 2021 | $43.47 | -51.5% |
| 2020 | $89.60 | +66.1% |
| 2019 | $53.95 | -9.0% |
| 2018 | $59.28 | +27.6% |
| 2017 | $46.47 | +41.5% |
Trading Range
The price is 13.5% below its 50-day average of $6.49 and 26.9% below its 200-day average of $7.68.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $5.61 | |
| 52-week high | $14.06 | -60.1% |
| 52-week low | $4.36 | +28.7% |
| 50-day average | $6.49 | -13.5% |
| 200-day average | $7.68 | -26.9% |
Price Risk
Over 3 years, its largest fall from a peak was 71.2%.
| Measure | Value |
|---|---|
| 1-year beta | 1.11 |
| Largest fall, 1 year | -68.0% |
| Largest fall, 3 years | -71.2% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About EBS
What is EBS's 1-year price change?
Emergent Biosolutions's price fell 44.5% over the past 12 months. With dividends included, the 12-month total return was -44.5%.
What is EBS's 5-year price change?
Emergent Biosolutions's month-end price fell 85.7% over the 5 years through Oct 2026, a compound annual decline of 32.2%. These figures leave out dividends.
What is EBS's 52-week high and low?
Emergent Biosolutions's 52-week high is $14.06 and its 52-week low is $4.36. Its latest price of $5.61 on Nov 17, 2026 is 60.1% below the high.
What is EBS's beta?
Emergent Biosolutions's 1-year beta against the S&P 500 is 1.11, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 68.0%.
Is the EBS chart free?
Yes. Advanced Charting for EBS is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
EBS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts